Considering these will ensure your investment translates to real health benefits
According to NICE guidance (NG28), GLP-1 receptor agonists like Ozempic are typically considered when triple therapy is ineffective, not tolerated or contraindicated, with specific BMI and clinical criteria
Recently, Zealand Pharma , a Danish biotechnology company, and Boehringer Ingelheim (BI) announced breakthrough clinical trial results for Survodutide , a novel drug targeting metabolic dysfunction-associated steatohepatitis (MASH)
While glucocorticoids suppress inflammation through the glucocorticoid receptor (GR), they also cause metabolic side effects
Appetite suppression is a hallmark of GLP-1 receptor agonists, which act on brain appetite centers and slow gastric emptying